-
1.
公开(公告)号:EP1301528A2
公开(公告)日:2003-04-16
申请号:EP01959046.2
申请日:2001-07-19
发明人: SAKSENA, Anil, K. , GIRIJAVALLABHAN, Viyyoor, Moopil , LOVEY, Raymond, G. , JAO, Edwin, E. , BENNETT, Frank , MCCORMICK, Jinping , WANG, Haiyan , PIKE, Russell, E. , BOGEN, Stephane, L. , LIU, Yi-Tsung , ARASAPPAN, Ashok , PAREKH, Tejal , PINTO, Patrick, A. , NJOROGE, F., George , GANGULY, Ashit, K. , BRUNCK, Terence, K. , KEMP, Scott, Jeffrey , LEVY, Odile, Esther , LIM-WILBY, Marguerita
摘要: The present invention discloses novel peptide compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such peptides as well as methods of using them to treat disorders associated with the HCV protease.
摘要翻译: 本发明公开了具有HCV蛋白酶抑制活性的新型肽化合物以及制备该化合物的方法。 在另一个实施方案中,本发明公开了包含此类肽的药物组合物以及使用它们治疗与HCV蛋白酶相关的病症的方法。
-
公开(公告)号:EP1100814A2
公开(公告)日:2001-05-23
申请号:EP99934173.8
申请日:1999-07-22
CPC分类号: C07K5/06069 , A61K38/00
摘要: Novel compounds having activity inhibitors of urokinase and in reducing or inhibiting blood vessel formation are provided. These compounds have an arginine or arginine mimic aldehyde or an arginine ketoamide group at P1. These compounds are useful in vitro for monitoring plasminogen activator levels and in vivo in treatment of conditions which are ameliorated by inhibition of or decreased activity of urokinase and in treating pathologic conditions wherein blood vessel formation is related to a pathologic condition.
-
公开(公告)号:EP0554383B1
公开(公告)日:2000-08-02
申请号:EP91920567.4
申请日:1991-10-17
IPC分类号: C12P21/08 , A61K39/395 , C12N5/20 , C07K7/00
摘要: Coagulation protein antagonists are disclosed, which include monoclonal-type antibodies and related cell lines disclosed for the production of specific, neutralizing antibodies against factors VII and VIIa and the tissue factor/factor VIIa bimolecular complex, which antibodies are useful for the prevention or treatment of thrombotic and related diseases, for immunoaffinity isolation and purification of factors VII and VIIa and the tissue factor/factor VIIa complex, and for determination of factors VII or VIIa and the tissue factor/factors VII or VIIa complex in a biological sample.
-
公开(公告)号:EP0554383A1
公开(公告)日:1993-08-11
申请号:EP91920567.0
申请日:1991-10-17
摘要: Les antagonistes de protéine de coagulation comprennent des anticorps monoclonaux et des lignées cellulaires apparentées pour la production d'anticorps spécifiques de neutralisation contre des facteurs VII et VIIa et le complexe bi-moléculaire facteur tissulaire/facteur VIIa, ces anticorps étant utiles à la prévention ou au traitement de maladies thrombotiques et autres maladies du même genre, à l'isolement par immunoaffinité et à la purification de facteurs VII et VIIa et du complexe facteur tissulaire/facteur VIIa, ainsi qu'à la détermination de facteurs VII ou VIIa et du complexe facteur tissulaire/facteurs VII ou VIIa dans un échantillon biologique.
-
-
-